L
Laura Layos
Publications - 27
Citations - 794
Laura Layos is an academic researcher. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 8, co-authored 22 publications receiving 584 citations.
Papers
More filters
Journal ArticleDOI
Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance
Eva Martinez-Balibrea,Anna Martínez-Cardús,Alba Ginés,Vicenç Ruiz de Porras,Catia Moutinho,Laura Layos,Jose Luis Manzano,Cristina Buges,Sara Bystrup,Manel Esteller,Manel Esteller,Albert Abad +11 more
TL;DR: This review will be focused on recent discoveries about oxaliplatin tumor-related resistance mechanisms, including alterations in transport, detoxification, DNA damage response and repair, cell death (apoptotic and nonapoptosis), and epigenetic mechanisms.
Journal ArticleDOI
Resistant mechanisms to BRAF inhibitors in melanoma
Jose Luis Manzano,Laura Layos,Cristina Buges,Maria de los Llanos Gil,Laia Vilà,Eva Martinez-Balibrea,Anna Martínez-Cardús +6 more
TL;DR: Mechanisms of resistance to targeted therapy and strategies to overcome them are commented on.
Journal ArticleDOI
Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway
Vicenç Ruiz de Porras,Sara Bystrup,Anna Martínez-Cardús,Raquel Pluvinet,Lauro Sumoy,Lynne M. Howells,Mark I. James,Chinenye Iwuji,Jose Luis Manzano,Laura Layos,Cristina Buges,Albert Abad,Eva Martinez-Balibrea +12 more
TL;DR: It is suggested that combination of OXA + Curcumin could be an effective treatment, for which CXCL1 could be used as a predictive marker, in CRC patients.
Journal ArticleDOI
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy
Eva Martinez-Balibrea,Albert Abad,Anna Martínez-Cardús,Alba Ginés,Manuel Valladares,Matilde Navarro,E. Aranda,Eugenio Marcuello,Manuel Benavides,B. Massuti,Alfredo Carrato,Laura Layos,Jose Luis Manzano,Victor Moreno +13 more
TL;DR: TYMS and UGT1A polymorphisms influence on tumour response and toxicities derived from irinotecan/5FU treatment in CRC patients is investigated and a genetic-based algorithm to optimise treatment individualisation is proposed.
Journal ArticleDOI
HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).
Margaret A. Tempero,Eric Van Cutsem,Darren Sigal,Do-Youn Oh,Nicola Fazio,Teresa Macarulla,Erika Hitre,Pascal Hammel,Andrew Eugene Hendifar,Susan E. Bates,Chung-Pin Li,Christelle De La Fouchardiere,Volker Heinemann,Anthony Maraveyas,Nathan Bahary,Laura Layos,Vaibhav Sahai,Lei Zheng,Jill Lacy,Andrea J. Bullock,Halo Investigators +20 more
TL;DR: A major component of the tumor microenvironment (TME) in PDA, PEGPH20 degrades tumor HA, remodeling the TME and shows antitumor activity and increased T...